Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Sunshine Biopharma Inc. Warrant (SBFMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: SBFMW (1-star) is a SELL. SELL since 5 days. Simulated Profits (-46.88%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 18 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.96 | 52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 |
52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.88% | Operating Margin (TTM) -14.56% |
Management Effectiveness
Return on Assets (TTM) -11.78% | Return on Equity (TTM) -21.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4553895 |
Shares Outstanding - | Shares Floating 4553895 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sunshine Biopharma Inc. Warrant
Company Overview
History and Background
Sunshine Biopharma Inc. Warrant represents a call option to purchase shares of Sunshine Biopharma Inc. (SBFG). Sunshine Biopharma Inc. itself is a pharmaceutical company focused on developing novel therapeutics for various diseases. The warrant's history is tied to the company's financing and stock issuance activities, typically offered to investors in conjunction with other securities or as part of private placements.
Core Business Areas
- Research and Development: Sunshine Biopharma Inc. focuses on the research and development of proprietary pharmaceuticals, particularly in the areas of oncology and infectious diseases. Their primary efforts are directed towards discovering and advancing new drug candidates through preclinical and clinical trials.
Leadership and Structure
Sunshine Biopharma Inc. is led by its executive management team and overseen by a Board of Directors. The specific leadership for the warrant itself is not applicable, as it is a financial instrument tied to the underlying company's performance and governance.
Top Products and Market Share
Key Offerings
- Sunshine Biopharma Inc. Warrant (SBFG.W): This is a financial instrument that grants the holder the right, but not the obligation, to purchase shares of Sunshine Biopharma Inc. (SBFG) at a specified price (exercise price) before a certain expiration date. Market share data is not applicable as it is a derivative security, not a product with direct market sales. Competitors for investment in this warrant would be other speculative or growth-oriented investments.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, long development cycles, stringent regulatory requirements, and significant market potential for successful drugs. The biotechnology sector, in particular, is driven by innovation and scientific breakthroughs.
Positioning
Sunshine Biopharma Inc., as an emerging biopharmaceutical company, is positioned in a highly competitive landscape. Its positioning is largely dependent on the success of its drug development pipeline. The warrant's attractiveness is directly linked to the perceived future value and potential upside of the underlying company's stock.
Total Addressable Market (TAM)
The TAM for Sunshine Biopharma Inc.'s potential drugs would depend on the specific indications they target (e.g., oncology, infectious diseases). These markets are generally large and growing. Sunshine Biopharma Inc. is a small player attempting to gain a foothold in these vast markets, with its success contingent on clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Focus on potentially high-impact therapeutic areas (oncology, infectious diseases).
- Proprietary drug development pipeline.
Weaknesses
- Early-stage company with unproven drug candidates.
- Limited financial resources compared to larger pharmaceutical companies.
- Reliance on successful clinical trials and regulatory approvals.
- The warrant itself has an expiration date and is subject to market volatility.
Opportunities
- Significant unmet medical needs in target disease areas.
- Potential for strategic partnerships or acquisitions by larger pharmaceutical firms.
- Advancements in biotechnology and drug delivery methods.
- Growth in the overall biopharmaceutical market.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and rejections.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Changes in healthcare policies and reimbursement.
- Market volatility affecting the value of the warrant and underlying stock.
Competitors and Market Share
Key Competitors
- Specialty Pharmaceuticals (e.g., Companies developing oncology drugs)
- Biotechnology Companies (e.g., Companies with similar R&D focuses)
Competitive Landscape
Sunshine Biopharma Inc. operates in a highly competitive biopharmaceutical landscape. Its competitive advantages, if any, would stem from the novelty of its drug candidates and the potential efficacy and safety profiles. However, it faces significant challenges from established players with vast resources and proven track records.
Growth Trajectory and Initiatives
Historical Growth: Sunshine Biopharma Inc.'s growth trajectory is tied to the progress of its drug development pipeline. This typically involves stages of scientific discovery, preclinical testing, and clinical trials. Growth is not measured in traditional revenue terms but in developmental milestones.
Future Projections: Future projections for Sunshine Biopharma Inc. are speculative and heavily contingent on the success of its lead drug candidates in clinical trials and subsequent regulatory approvals. Analyst estimates, if available, would be highly variable.
Recent Initiatives: Recent initiatives for Sunshine Biopharma Inc. likely involve advancing specific drug candidates through their respective development phases, seeking regulatory feedback, and potentially engaging in further fundraising activities.
Summary
Sunshine Biopharma Inc. Warrant is a speculative investment tied to the success of its parent company, Sunshine Biopharma Inc. The company operates in the highly competitive biopharmaceutical sector, focusing on R&D for oncology and infectious diseases. Its strengths lie in its focused pipeline, but it faces significant weaknesses due to its early-stage status and reliance on clinical trial outcomes. Investors should be aware of the inherent risks and volatility associated with such investments.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news outlets
- Industry analysis reports
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Investment in warrants and early-stage biopharmaceutical companies carries significant risk of loss. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc. Warrant
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2022-02-15 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.